RxDoctor Payments Data

Holly Jones, APRN

Family · Branford, FLNPI 1457749897

Payments from drug & device makers

$2,683in general payments, 2019–2025

Across 154 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$862
  • AstraZeneca$397
  • Boehringer Ingelheim$359
  • AbbVie$271
  • Novo Nordisk$213
  • Exact Sciences$158
  • plus $423 from 10 others

What the payments were for

  • Food & beverage$2,66499%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,683 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$4,834
Medicare patients
124
Services billed
335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide89$122,962
JardianceEmpagliflozin62$95,042
OzempicSemaglutide53$68,844
TrulicityDulaglutide44$59,345
FarxigaDapagliflozin Propanediol49$56,615
EliquisApixaban46$55,096
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$37,206
XareltoRivaroxaban24$30,754
TradjentaLinagliptin16$22,279
SymbicortBudesonide/Formoterol Fumarate45$19,916
MyrbetriqMirabegron22$17,264
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$16,158
Spiriva HandihalerTiotropium Bromide15$13,297
Breo ElliptaFluticasone/Vilanterol13$10,891
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$9,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$862$182,307133 claims
Boehringer IngelheimJardiance, Tradjenta$359$117,32178 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$397$92,689105 claims
Novo NordiskOzempic$213$68,84453 claims
PfizerEliquis$109$55,09646 claims
GSKTrelegy Ellipta, Breo Ellipta$65$48,09864 claims
MerckJanuvia$58$6,51412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.

Other family in Branford

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →